“Independent” Drug Safety Office Is Goal Of Senate Vioxx Investigation
Executive Summary
The idea of an "independent" drug safety office in FDA merits consideration, Office of New Drugs Acting Director Sandra Kweder, MD, said during the Senate Finance Committee hearing Nov. 18 on Merck's withdrawal of Vioxx
You may also be interested in...
Crawford’s First Business After Confirmation: Brief Senators On Mifeprex
FDA Commissioner Lester Crawford's first business following his confirmation was to brief members of Congress about reports of deaths in patients using Danco Laboratories' abortifacientMifeprex
Crawford’s First Business After Confirmation: Brief Senators On Mifeprex
FDA Commissioner Lester Crawford's first business following his confirmation was to brief members of Congress about reports of deaths in patients using Danco Laboratories' abortifacientMifeprex
FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals
Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals